ABSTRACT
The present study examined the preliminary effects of an 8-session group cognitive-behavioral treatment (CBT) designed to reduce driving-related anger, aggression, and risky driving behaviors in veterans. Participants (N = 9) with self-reported aggressive and risky driving problems completed self-report measures at pretreatment, posttreatment, and 1-month follow-up. Of those completing the treatment, 89% demonstrated reliable change in driving-related aggression and 67% evidenced reliable change in driving-related anger. Similar changes were found for secondary treatment targets.
Subject(s)
Affective Symptoms/therapy , Cognitive Behavioral Therapy , Psychotherapy, Group , Veterans/psychology , Adult , Aged , Aggression/psychology , Anger , Automobile Driving/psychology , Humans , Middle Aged , Patient Satisfaction , Pilot Projects , Psychiatric Status Rating Scales , Risk-TakingABSTRACT
OBJECTIVES: To review existing literature about the psychosocial reactions of cancer patients and provide information about the needs of patients wishing to preserve fertility. DATA SOURCES: Journal articles, research studies. CONCLUSION: The desire for biological parenthood is an important issue for cancer survivors. Patients may not receive accurate, timely information about fertility-sparing options; those not receiving this information are at increased risk for psychological distress. IMPLICATIONS FOR NURSING PRACTICE: Fertility-preservation decisions are complex and a team approach may identify patients at risk for psychological distress and provide opportunities for discussion of psychosocial issues involved. Nurses must be informed about the emotional reactions and informational needs of their patients.
Subject(s)
Infertility/nursing , Infertility/psychology , Neoplasms/nursing , Neoplasms/psychology , Oncology Nursing , Affective Symptoms/nursing , Affective Symptoms/psychology , Female , Humans , Male , Psychology , Reproductive Techniques, Assisted/nursing , Reproductive Techniques, Assisted/psychology , Survivors/psychologyABSTRACT
The anti-CD20 monoclonal antibody, rituximab, and interferon alpha (IFN) are active agents in advanced stage, indolent lymphoma. Some data obtained in vitro suggest upregulation of CD20 by IFN, and clinical trials have reported additive or synergistic activity of IFN with rituximab. A prospective phase II study in advanced stage, follicular and non-follicular indolent lymphoma was performed. Peginterferon alpha 2b (pegIFN) 0.5 microg/kg s.c. weekly x 6 and rituximab 375 mg/m2 i.v. weekly x 4 (beginning on week 3 of pegIFN) was administered. Quantitative CD20 antigen was measured pre-treatment and pre-rituximab in lymph node aspirates. Nine patients were treated: one complete response and three partial responses; however, all relapsed within 12 months and two were withdrawn for grade 3 toxicity (both with serum sickness). No up-regulation of CD20 was documented in seven patients studied (median change in CD20: decrease by 11.9%). PegIFN plus rituximab as delivered in this study is not recommended. PegIFN does not appear to upregulate CD20 expression in peripheral lymph node tumor cells.
